These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 17889411)
1. Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Puig-Barberà J; Díez-Domingo J; Varea AB; Chavarri GS; Rodrigo JA; Hoyos SP; Vidal DG Vaccine; 2007 Oct; 25(42):7313-21. PubMed ID: 17889411 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Puig-Barberà J; Diez-Domingo J; Pérez Hoyos S; Belenguer Varea A; González Vidal D Vaccine; 2004 Dec; 23(3):283-9. PubMed ID: 15530669 [TBL] [Abstract][Full Text] [Related]
4. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. de Bruijn I; Meyer I; Gerez L; Nauta J; Giezeman K; Palache B Vaccine; 2007 Dec; 26(1):119-27. PubMed ID: 18063446 [TBL] [Abstract][Full Text] [Related]
5. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Ruf BR; Colberg K; Frick M; Preusche A Infection; 2004 Aug; 32(4):191-8. PubMed ID: 15293073 [TBL] [Abstract][Full Text] [Related]
6. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Podda A; Del Giudice G Expert Rev Vaccines; 2003 Apr; 2(2):197-203. PubMed ID: 12899571 [TBL] [Abstract][Full Text] [Related]
7. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis. Domnich A; Arata L; Amicizia D; Puig-Barberà J; Gasparini R; Panatto D Vaccine; 2017 Jan; 35(4):513-520. PubMed ID: 28024956 [TBL] [Abstract][Full Text] [Related]
9. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Del Giudice G; Hilbert AK; Bugarini R; Minutello A; Popova O; Toneatto D; Schoendorf I; Borkowski A; Rappuoli R; Podda A Vaccine; 2006 Apr; 24(16):3063-5. PubMed ID: 16464520 [TBL] [Abstract][Full Text] [Related]
10. Is the adjuvanted influenza vaccine more effective than the trivalent inactivated vaccine in the elderly population? Results of a case-control study. Spadea A; Unim B; Colamesta V; Meneghini A; D'Amici AM; Giudiceandrea B; La Torre G Vaccine; 2014 Sep; 32(41):5290-4. PubMed ID: 25087677 [TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic evaluation of the MF59--adjuvanted influenza vaccine in the elderly population in Italy. Iannazzo S J Prev Med Hyg; 2011 Mar; 52(1):1-8. PubMed ID: 21710816 [TBL] [Abstract][Full Text] [Related]
12. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages. Camilloni B; Neri M; Lepri E; Iorio AM Vaccine; 2009 Jun; 27(31):4099-103. PubMed ID: 19410623 [TBL] [Abstract][Full Text] [Related]
13. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. Baldo V; Baldovin T; Floreani A; Carraro AM; Trivello R; Vaccine; 2007 May; 25(20):3955-61. PubMed ID: 17383057 [TBL] [Abstract][Full Text] [Related]
14. Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. de Roux A; Marx A; Burkhardt O; Schweiger B; Borkowski A; Banzhoff A; Pletz MW; Lode H Vaccine; 2006 Mar; 24(10):1537-42. PubMed ID: 16288937 [TBL] [Abstract][Full Text] [Related]
15. MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system. Puig-Barberà J; Natividad-Sancho A; Calabuig-Pérez J; Lluch-Rodrigo JA; Pastor-Villalba E; Martínez-Úbeda S; Pérez-Vilar S; Díez-Domingo J Vaccine; 2013 Aug; 31(37):3995-4002. PubMed ID: 23731629 [TBL] [Abstract][Full Text] [Related]
16. [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly]. Li RC; Fang HH; Li YP; Liu YP; Nong Y; Huang GB Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):548-51. PubMed ID: 19040034 [TBL] [Abstract][Full Text] [Related]
17. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Ansaldi F; Bacilieri S; Durando P; Sticchi L; Valle L; Montomoli E; Icardi G; Gasparini R; Crovari P Vaccine; 2008 Mar; 26(12):1525-9. PubMed ID: 18294741 [TBL] [Abstract][Full Text] [Related]
18. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Durando P; Icardi G; Ansaldi F Expert Opin Biol Ther; 2010 Apr; 10(4):639-51. PubMed ID: 20218923 [TBL] [Abstract][Full Text] [Related]
19. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Van Buynder PG; Konrad S; Van Buynder JL; Brodkin E; Krajden M; Ramler G; Bigham M Vaccine; 2013 Dec; 31(51):6122-8. PubMed ID: 23933368 [TBL] [Abstract][Full Text] [Related]
20. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Pellegrini M; Nicolay U; Lindert K; Groth N; Della Cioppa G Vaccine; 2009 Nov; 27(49):6959-65. PubMed ID: 19751689 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]